View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Covid-19 Vaccination

Latest news, daily rates, information and updates

Last updated 22 May, 2022 10:30 CEST

As the coronavirus vaccine rolls out across the globe on this page you will find all our latest Covid-19 vaccine updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

11,766,096,641

+2,749,821 reported yesterday

Number of fully vaccinated globally

4,709,598,896

+1,233,365 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

0.9%

+0% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 11,766,096,641 1,549.3 6202 %
China 3,370,162,000 2,419.8 8994 % CanSino, IMBCAMS, KCONVAC, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001
India 1,922,077,507 1,421.0 6515 % Covaxin, Oxford/AstraZeneca, Sputnik V
United States 584,279,990 1,785.9 6752 % Johnson&Johnson, Moderna, Pfizer/BioNTech
Brazil 437,142,038 2,086.9 7902 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Indonesia 401,308,016 1,499.3 6233 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Japan 278,300,970 2,199.5 8057 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bangladesh 259,689,592 1,609.4 7254 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Pakistan 248,429,799 1,170.7 5792 % CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Vietnam 216,959,400 2,270.9 8235 % Abdala, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Mexico 206,941,649 1,639.9 6335 % CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Germany 179,723,148 2,167.2 7776 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Russia 166,676,353 1,142.1 5042 % EpiVacCorona, Sputnik V
Iran 149,698,995 1,782.3 6879 % Covaxin, COVIran Barekat, FAKHRAVAC, Oxford/AstraZeneca, Razi Cov Pars, Sinopharm/Beijing, Soberana02, SpikoGen, Sputnik V
Philippines 148,929,189 1,396.4 6461 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Turkey 147,678,580 1,794.0 6445 % Pfizer/BioNTech, Sinovac, Turkovac
France 144,192,526 2,152.5 7881 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
United Kingdom 142,045,948 2,136.4 7475 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Italy 137,430,342 2,274.2 7930 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Thailand 135,817,331 1,956.2 7506 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
South Korea 125,182,129 2,424.4 8632 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Argentina 101,147,280 2,273.3 8402 % CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Spain 94,653,236 2,025.8 8663 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Canada 84,952,660 2,292.4 8461 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Colombia 79,932,662 1,610.0 6948 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Malaysia 70,799,796 2,196.9 8379 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Peru 68,130,603 2,129.8 8172 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Saudi Arabia 64,913,471 1,926.2 7373 % Oxford/AstraZeneca, Pfizer/BioNTech
Australia 57,529,212 2,301.9 8640 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Myanmar 56,989,806 1,061.1 4530 % Oxford/AstraZeneca, Sinopharm/Beijing
Chile 55,162,264 2,945.3 9345 % CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Morocco 54,528,504 1,513.5 6493 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Poland 54,437,812 1,433.4 5919 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Taiwan 54,170,932 2,294.4 7999 % Medigen, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Uzbekistan 50,434,421 1,530.4 4503 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik Light, Sputnik V, ZF2001
Nepal 42,516,879 1,513.7 7032 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Nigeria 41,091,354 209.8 859 % Oxford/AstraZeneca
Sri Lanka 39,102,567 1,804.5 6639 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Venezuela 37,860,994 1,311.4 4949 % Abdala, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V
Cambodia 37,654,417 2,317.2 8709 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Egypt 36,906,765 360.6 1370 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Cuba 36,498,822 3,219.1 8785 % Abdala, Soberana Plus, Soberana02
South Africa 35,740,663 618.6 3228 % Johnson&Johnson, Pfizer/BioNTech
Netherlands 34,017,698 1,974.2 7175 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Ukraine 31,683,310 710.0 3411 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Mozambique 31,616,078 1,071.9 4744 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Ethiopia 29,373,478 268.9 1919 % Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Belgium 25,336,921 2,218.2 8004 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
United Arab Emirates 24,812,581 2,518.9 9840 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
Ecuador 24,662,847 1,443.6 6535 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Portugal 22,923,599 2,229.5 9157 % Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Sweden 22,361,635 2,195.9 7502 % Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Greece 20,985,720 1,956.2 7106 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Kazakhstan 20,918,681 1,144.6 5072 % QazVac, Sinopharm/Beijing, Sputnik V
Uganda 20,899,440 489.2 2491 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Rwanda 20,141,669 1,637.3 6861 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Austria 18,336,033 2,072.6 7479 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Israel 18,150,178 2,043.1 6911 % Moderna, Pfizer/BioNTech
Kenya 17,992,422 350.1 1672 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Iraq 17,906,725 465.9 1900 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Czechia 17,618,574 1,658.1 6468 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Guatemala 17,289,566 1,002.4 3589 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Romania 16,802,118 862.8 4162 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hungary 16,530,488 1,692.2 6342 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Hong Kong 16,453,534 2,176.4 8272 % Pfizer/BioNTech, Sinovac
Switzerland 15,700,229 1,843.5 7042 % Johnson&Johnson, Moderna, Pfizer/BioNTech
Dominican Republic 15,639,972 1,471.7 5622 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Ghana 14,872,174 499.6 2058 % Oxford/AstraZeneca, Sputnik V
Angola 14,588,435 473.5 1536 % Oxford/AstraZeneca
Singapore 14,055,906 2,492.8 8842 % Moderna, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Honduras 13,927,995 1,452.7 5669 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Azerbaijan 13,698,183 1,377.8 4874 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Denmark 13,220,825 2,280.5 8274 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bolivia 13,147,393 1,158.0 5118 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Tunisia 13,025,166 1,126.2 5483 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Belarus 12,807,687 1,350.3 6392 % KoviVac/Chumakov, Sinopharm/Beijing, Sputnik Light, Sputnik V
Cote d'Ivoire 12,387,947 494.1 2172 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Finland 11,771,112 2,133.2 7836 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Zimbabwe 11,654,822 807.2 3090 % Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Norway 11,314,876 2,129.1 7596 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
New Zealand 11,074,631 2,266.8 8395 % Oxford/AstraZeneca, Pfizer/BioNTech
Costa Rica 10,909,597 2,182.2 8264 % Oxford/AstraZeneca, Pfizer/BioNTech
Ireland 10,904,913 2,246.8 8306 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Laos 10,804,053 1,485.0 6884 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
El Salvador 10,680,432 1,663.4 6694 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Nicaragua 10,487,916 1,622.1 7351 % Abdala, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Soberana02, Sputnik Light, Sputnik V
Algeria 9,989,662 236.6 989 % Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Jordan 9,896,497 994.0 4505 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Serbia 8,527,016 1,221.3 4692 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Paraguay 8,428,214 1,211.6 4768 % Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Uruguay 8,302,563 2,407.0 8328 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Panama 8,167,735 1,955.5 7409 % Oxford/AstraZeneca, Pfizer/BioNTech
Kuwait 8,002,689 1,934.3 7985 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Slovakia 7,070,767 1,298.1 5080 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Qatar 6,852,769 2,463.5 9355 % Moderna, Pfizer/BioNTech
Oman 6,600,551 1,366.7 6144 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Afghanistan 6,066,579 163.2 1267 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Mongolia 5,492,919 1,732.7 6863 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Lebanon 5,310,268 775.3 3235 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Sudan 5,251,235 125.6 295 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Croatia 5,250,948 1,284.0 5486 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Tajikistan 5,059,324 555.9 2496 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Zambia 4,656,681 268.4 1692 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Lithuania 4,483,482 1,607.3 6723 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Bulgaria 4,395,129 625.7 2931 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Palestine 3,707,619 726.8 3455 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Bahrain 3,439,499 2,191.5 7771 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Libya 3,369,226 504.5 1658 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Togo 3,290,821 417.1 1974 % Oxford/AstraZeneca
Kyrgyzstan 3,077,472 487.3 2051 % Sinopharm/Beijing, Sputnik V
Slovenia 2,992,810 1,447.6 5910 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Burkina Faso 2,928,989 140.6 739 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Latvia 2,889,300 1,499.7 6773 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Georgia 2,888,622 774.2 3393 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Niger 2,845,107 126.8 691 % Oxford/AstraZeneca, Sinopharm/Beijing
Albania 2,840,948 991.1 4311 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Somalia 2,677,716 178.4 923 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Mauritania 2,650,000 601.8 2457 % Oxford/AstraZeneca, Sinopharm/Beijing
Senegal 2,469,499 155.8 663 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Guinea 2,443,497 196.8 640 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Tanzania 2,431,769 43.2 241 % Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing
Madagascar 2,369,775 90.2 441 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Malawi 2,166,402 119.4 628 % Johnson&Johnson, Oxford/AstraZeneca
Moldova 2,144,104 604.7 2989 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Mauritius 2,077,156 1,641.6 7235 % Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Estonia 1,987,124 1,504.4 6404 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Botswana 1,920,000 851.8 5943 % Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Kosovo 1,828,499 990.9 4459 % Oxford/AstraZeneca, Pfizer/BioNTech
Mali 1,814,171 95.1 564 % Oxford/AstraZeneca
Cyprus 1,761,882 1,390.9 5075 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Armenia 1,761,529 596.8 2659 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik Light, Sputnik V
North Macedonia 1,675,793 804.5 3792 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik V
Trinidad and Tobago 1,558,497 1,121.3 5125 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Fiji 1,466,908 1,660.4 7184 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Jamaica 1,432,806 488.2 2370 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Macao 1,392,157 2,204.0 9049 % Pfizer/BioNTech, Sinopharm/Beijing
Syria 1,342,360 76.7 413 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Malta 1,292,843 2,673.8 9699 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Luxembourg 1,285,351 2,115.0 5924 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Bosnia and Herzegovina 1,242,203 373.7 1528 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Benin 1,144,390 99.6 764 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Cameroon 1,024,333 40.6 263 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Bhutan 1,010,129 1,339.0 6305 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Sierra Leone 923,880 120.8 504 % Oxford/AstraZeneca, Sinopharm/Beijing
Guyana 905,748 1,162.7 4702 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Namibia 834,756 341.0 1667 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Congo 830,379 9.9 65 % Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Iceland 805,469 2,278.1 8207 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Brunei 790,506 1,701.9 8298 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Yemen 784,792 27.5 135 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Maldives 772,056 1,497.1 7060 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Cape Verde 758,359 1,364.0 5527 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
South Sudan 723,341 65.9 575 % Johnson&Johnson, Oxford/AstraZeneca
Gambia 720,698 316.1 1484 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Lesotho 688,097 326.4 3041 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Montenegro 673,378 1,082.0 4550 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Central African Republic 652,134 139.8 1178 % Covaxin, Oxford/AstraZeneca
Northern Cyprus 617,389 1,657.5 7409 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Comoros 598,000 718.5 3087 % Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Liberia 589,628 122.4 948 % Oxford/AstraZeneca
Papua New Guinea 586,000 68.1 306 % Oxford/AstraZeneca
Gabon 566,021 267.1 817 % Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Guinea-Bissau 562,296 300.0 1821 % Oxford/AstraZeneca, Sinopharm/Beijing
Suriname 505,189 877.1 4125 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Samoa 477,369 2,433.9 9274 % Oxford/AstraZeneca
Belize 475,163 1,240.4 5524 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
New Caledonia 460,435 1,580.3 6181 % Pfizer/BioNTech
Democratic Republic of Congo 457,160 5.4 25 % Oxford/AstraZeneca
French Polynesia 452,385 1,629.2 6511 % Johnson&Johnson, Pfizer/BioNTech
Equatorial Guinea 443,135 338.5 1502 % Sinopharm/Beijing
Eswatini 434,201 382.2 2808 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Solomon Islands 425,059 651.1 2152 % Oxford/AstraZeneca
Chad 381,189 24.6 62 % Sinopharm/Beijing
Bahamas 339,546 880.5 4085 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Barbados 314,737 1,098.0 5322 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Vanuatu 301,000 1,028.4 4037 % Oxford/AstraZeneca
Curacao 252,604 1,580.3 6209 % Moderna, Pfizer/BioNTech
Jersey 233,982 2,170.5 7461 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Seychelles 199,466 2,061.4 8298 % Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Sao Tome and Principe 195,925 928.4 4119 % Oxford/AstraZeneca
Haiti 190,063 17.1 63 % Johnson&Johnson, Moderna
Isle of Man 189,681 2,256.0 7972 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Djibouti 185,126 193.1 1298 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Tonga 181,220 1,714.6 6798 % Oxford/AstraZeneca
Aruba 170,938 1,615.0 7769 % Pfizer/BioNTech
Guernsey 155,684 2,482.8 2172 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bermuda 131,612 2,057.5 7450 % Oxford/AstraZeneca, Pfizer/BioNTech
Cayman Islands 125,717 1,959.0 8755 % Oxford/AstraZeneca, Pfizer/BioNTech
Saint Lucia 120,345 661.6 2958 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Gibraltar 119,578 3,546.4 12279 % Oxford/AstraZeneca, Pfizer/BioNTech
Antigua and Barbuda 115,487 1,199.4 5681 % Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Faeroe Islands 103,894 0 % Moderna, Pfizer/BioNTech
Grenada 88,384 793.0 3438 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Greenland 79,745 1,423.4 6872 % Moderna, Pfizer/BioNTech
Liechtenstein 70,232 1,852.6 6952 % Johnson&Johnson, Moderna, Pfizer/BioNTech
Saint Vincent and the Grenadines 70,032 635.4 2750 % Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik Light, Sputnik V
Dominica 66,558 929.3 4224 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Saint Kitts and Nevis 60,467 1,136.1 4940 % Oxford/AstraZeneca, Pfizer/BioNTech
Sint Maarten (Dutch part) 51,856 1,275.5 6130 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Monaco 49,980 1,292.1 6026 % Pfizer/BioNTech
Turks and Caicos Islands 49,107 1,303.8 6235 % Pfizer/BioNTech
San Marino 47,100 1,394.1 7233 % Pfizer/BioNTech, Sputnik V
Turkmenistan 41,993 7.0 16 % EpiVacCorona, Oxford/AstraZeneca, QazVac, Sinopharm/Beijing, Sputnik V, ZF2001
Anguilla 23,492 1,300.3 5532 % Oxford/AstraZeneca, Pfizer/BioNTech
Nauru 22,976 1,808.6 6758 % Oxford/AstraZeneca
Andorra 19,064 247.6 164 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Wallis and Futuna 16,376 1,035.9 4084 % Moderna
Burundi 12,651 1.1 11 % Johnson&Johnson, Sinopharm/Beijing
Bonaire Sint Eustatius and Saba 7,391 275.7 621 % Moderna, Pfizer/BioNTech
Tuvalu 4,772 405.0 0 % Oxford/AstraZeneca
Falkland Islands 4,322 1,070.1 4251 % Oxford/AstraZeneca
Saint Helena 3,107 393.1 0 % Oxford/AstraZeneca
Montserrat 1,306 243.7 362 % Oxford/AstraZeneca
Timor-Leste 0 0.0 0 %
Eritrea 0 0.0 0 %
Marshall Islands 0 0.0 0 %
Micronesia (country) 0 0.0 0 %
Vatican 0 0.0 0 %

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 47

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of COVID-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation in some regions.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
8 Apr, 2022: Emergency Use Authorization given by Australia
29 Mar, 2022: Emergency Use Authorization given by the US
24 Mar, 2022: Complete Approval given by Japan
23 Feb, 2022: Emergency Use Authorization given by South Korea
30 Jan, 2022: Complete Approval given by Qatar
28 Jan, 2022: Emergency Use Authorization given by Australia
21 Jan, 2022: Emergency Use Authorization given by Japan
09 Jan, 2022: Complete Approval given by Qatar
06 Jan, 2022: Emergency Use Authorization given by Malaysia
06 Jan, 2022: Complete Approval given by Brazil
04 Jan, 2022: Emergency Use Authorization given by US
22 Dec, 2021: Complete Approval given by UK
11 Dec, 2021: Emergency Use Authorization given by Singapore
10 Dec, 2021: Complete Approval given by Switzerland
09 Dec, 2021: Emergency Use Authorization given by US
08 Dec, 2021: Emergency Use Authorization given by South Africa
07 Dec, 2021: Complete Approval given by Spain
05 Dec, 2021: Emergency Use Authorization given by Australia
02 Dec, 2021: Emergency Use Authorization given by Italy
28 Nov, 2021: Complete Approval given by Egypt
19 Nov, 2021: Complete Approval given by Canada
19 Nov, 2021: EUA Approval given by US
10 Nov, 2021: Complete Approval given by Japan
9 Nov, 2021: Complete Approval given by Canada
01 Nov, 2021: Emergency Use Authorization given by South Africa
29 Oct, 2021: Emergency Use Authorization given by US
27 Oct, 2021: Emergency Use Authorization given by Australia
8 Oct, 2021: Emergency Use Authorization given by Malaysia
22 Sep, 2021: Emergency Use Authorization given by US
16 Sep, 2021: Complete Approval given by Canada
23 Jun, 2021: Emergency Use Authorization given by Australia
15 Jul, 2021: Emergency Use Authorization given by Indonesia
24 Jun, 2021: Emergency Use Authorization given by Thailand
21 Jun, 2021: Complete Approval given by New-Zealand
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Complete Approval given by US
12 Jun, 2021: Emergency Use Authorization given by Vietnam
11 Jun, 2021: Complete Approval given by Brazil
4 Jun, 2021: Emergency Use Authorization given by UK
2 Jun, 2021: Emergency Use Authorization given by Zambia
31 May, 2021: Emergency Use Authorization given by Pakistan
31 May, 2021: Emergency Use Authorization given by Italy
28 May,2021: Complete Approval given by EU
27 May, 2021: Emergency Use Authorization given by Bangladesh
13 May, 2021: Emergency Use Authorization given by United Arab Emirates
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
21 Mar, 2021: Emergency Use Authorization given by Libya
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
25 Dec, 2020: Emergency Use Authorization given by Ireland
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 31

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of COVID-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
17 Apr, 2022: Emergency Use Authorization given by the Taiwan
14 Apr, 2022: Emergency Use Authorization given by the UK
29 Mar, 2022: Emergency Use Authorization given by the US
17 Mar, 2022: Complete Approval given by Canada
03 Mar, 2022: Complete Approval given by EU
16 Feb, 2022: Emergency Use Authorization given by Australia
08 Feb, 2022: Emergency Use Authorization given by Colombia
2 Feb, 2022: Complete Approval given by the US
16 Dec, 2021: Complete Approval given by Japan
8 Dec, 2021: Emergency Use Authorization given by Australia
19 Nov, 2021: Emergency Use Authorization given by US
12 Nov, 2021: Complete Approval given by Canada
20 Oct, 2021: Emergency Use Authorization given by the US
5 Oct, 2021: Emergency Use Authorization given by EU
16 Sep, 2021: Complete Approval given by Canada
5 Sep, 2021: Emergency Use Authorization given by Australia
4 Sep, 2021: Emergency Use Authorization given by Philippines
19 Aug, 2021: Emergency Use Authorization given by Mexico
13 Aug, 2021: Emergency Use Authorization given by US
9 Aug, 2021: Emergency Use Authorization given by Australia
5 Aug, 2021: Emergency Use Authorization given by Malaysia
30 Jul, 2021: Emergency Use Authorization given by Lithuania
2 Jul, 2021: Emergency Use Authorization given by Italy
26 Jul, 2021: Emergency Use Authorization given by Bhutan
9 Jul, 2021: Emergency Use Authorization given by Saudia Arabia
4 Jul, 2021: Emergency Use Authorization given by United Arab Emirates
2 Jul, 2021: Emergency Use Authorization given by Indonesia
30 Jun, 2021: Emergency Use Authorization given by India
30 Jun, 2021: Emergency Use Authorization given by Bangladesh
29 Jun, 2021: Emergency Use Authorization given by Vietnam
8 Jun, 2021: Emergency Use Authorization given by Maldives
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
6 May, 2021: Emergency Use Authorization given by Taiwan
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
21 Mar, 2021: Emergency Use Authorization given by Libya
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4 54

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, schedule and SARS-CoV-2 variant. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
01 Feb, 2022: Emergency Use Authorization given by Thailand
27 Jan, 2022: Emergency Use Authorization given by India
15 Jan, 2022: Complete Approval given by Oman
17 Nov, 2021: Emergency Use Authorization given by Malaysia
14 Nov, 2021: Emergency Use Authorization given by Bahrain
28 Jul, 2021: Emergency Use Authorization given by New Zealand
2 Jun, 2021: Emergency Use Authorization given by Zambia
21 May, 2021: Emergency Use Authorization given by Japan
21 Mar, 2021: Emergency Use Authorization given by Libya
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
12 Feb, 2021: Emergency Use Authorization given by Cambodia
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
24 Jan, 2021: Emergency Use Authorization given by Ecuador
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 90.4% 14

Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
13 Apr, 2022: Emergency Use Authorization given by Switzerland
08 Apr, 2022: Emergency Use Authorization given by Thailand
22 Mar, 2022: Emergency Use Authorization given by India
10 Mar, 2022: Restricted Emergency Use Authorization given by India
17 Feb, 2022: Emergency Use Authorization given by Canada
14 Feb, 2022: Emergency Use Authorization given by Singapore
03 Feb, 2022: Emergency Use Authorization given by New Zealand
03 Feb, 2022: Complete Approval given by UK
19 Jan, 2022: Emergency Use Authorization given by Australia
13 Jan, 2022: Complete Approval given by South Korea
28 Dec, 2021: Restricted Emergency Use Authorization given by India
24 Dec, 2021: Emergency Use Authorization given by Netherlands
20 Dec, 2021: Emergency Use Authorization given by EU
17 Dec, 2021: Emergency Use Listing given by WHO
18 Nov, 2021: Emergency Use Authorization given by Philippine
Today

Johnson & Johnson 44,325 1 2 - 8°C 66.0% 32

Adenoviral vaccine able to confer nearly 70% protection against all COVID-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
27 Feb, 2022: Emergency Use Listing (EUL) given by WHO
27 Feb, 2022: Emergency Use Authorization given by the US
24 Nov, 2021: Complete Approval given by Canada
21 Oct, 2021: Emergency Use Authorization given by the US
16 Sep, 2021: Emergency Use Authorization given by Iran
07 Sep, 2021: Emergency Use Authorization given by Indonesia
07 Aug, 2021: Emergency Use Authorization given by India
28 Jul, 2021: Emergency Use Authorization given by Zimbabwe
15 Jul, 2021: Emergency Use Authorization given by Vietnam
7 Jul, 2021: Provisional approval given by New Zealand
5 Jul, 2021: Emergency Use Authorization given by Ukraine
25 Jun, 2021: Provisional approval given by Australia
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Emergency Use Authorization given by Bangladesh
11 Jun, 2021: Emergency Use Authorization given by Chile
8 Jun, 2021: Emergency Use Authorization given by Kuwait
8 Jun, 2021: Emergency Use Authorization given by Maldives
2 Jun, 2021: Emergency Use Authorization given by Zambia
28 May, 2021: Conditional Marketing Authorization given by UK
28 May, 2021: Emergency Use Authorization given by Mexico
20 Apr, 2021: Emergency Use Authorization given by Philippines
8 Apr, 2021: Emergency Use Authorization given by Tunisia
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
1 Apr, 2021: Emergency Use Authorization given by Brazil
21 Mar, 2021: Emergency Use Authorization given by Libya
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.7% 28

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
14 Mar, 2022: Emergency Use Authorization given by Philippine
04 Mar, 2022: Emergency Use Authorization given by Malaysia
05 Feb, 2022: Emergency Use Authorization given by Thailand
01 Feb, 2022: Emergency Use Authorization given by Thailand
20 Jan, 2022: Emergency Use Authorization given by Brazil
20 Nov, 2021: Emergency Use Authorization given by Hong Kong
17 Nov, 2021: Emergency Use Authorization given by Malaysia
12 Nov, 2021: Emergency Use Authorization given by Pakistan
1 Oct, 2021: Emergency Use Authorization given by Malaysia
9 Sep, 2021: Emergency Use Authorization given by Chile
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
17 Jul, 2021: Emergency Use Authorization given by Sri Lanka
3 Jul, 2021: Emergency Use Authorization given by South Africa
24 Jun, 2021: Emergency Use Authorization given by Oman
11 Jun, 2021: Emergency Use Authorization given by China
6 Jun, 2021: Emergency Use Authorization given by Bangladesh
4 Jun, 2021: Emergency Use Authorization given by Nepal
2 Jun, 2021: Emergency use listing (EUL) given by WHO
27 Apr, 2021: Emergency Use Authorization given by Egypt
10 Apr, 2021: Emergency Use Authorization given by Pakistan
9 Apr, 2021: Emergency Use Authorization given by Panama
10 Mar, 2021: Complete Approval given by Ukraine
10 Mar, 2021: Emergency Use Authorization given by Zimbabwe
05 Mar, 2021: Complete Approval given by Tunisia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Hong Kong
26 Feb, 2021: Emergency Use Authorization given by Ecuador
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
6 Feb, 2021: Emergency Use Authorization given by Lao People's Democratic Republic
6 Feb, 2021: Emergency Use Authorization given by Uruguay
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Gamaleya - Sputnik V 33,758 2 2 - 8°C 91.4% 77

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all COVID-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
02 Apr, 2022: Complete Approval given by Russia
04 Feb, 2022: Complete Approval given by Russia
31 Oct, 2021: Emergency Use Authorization given by Cambodia
25 Aug, 2021: Emergency Use Authorization given by Indonesia
21 Jul, 2021: Emergency Use Authorization given by Chile
15 Jul, 2021: Emergency Use Authorization given by Nigeria
24 Jun, 2021: Emergency Use Authorization given by Oman
5 Jun, 2020: Conditional Approval given by Brazil
15 May, 2021: Emergency Use Authorization given by Republic of Ecuador
13 May, 2021: Emergency Use Authorization given by Maldives
30 Apr, 2021: Emergency Use Authorization given by Turkey
30 Apr, 2021: Emergency Use Authorization given by Albania
27 Apr, 2021: Emergency Use Authorization given by Bangladesh
20 Apr, 2021: Emergency Use Authorization given by Nepal
12 Apr, 2021: Emergency Use Authorization given by India
1 Apr, 2021: Emergency Use Authorization given by Panama
30 Mar, 2021: Emergency Use Authorization given by Mali
26 Mar, 2021: Emergency Use Authorization given by Antigua
26 Mar, 2021: Emergency Use Authorization given by Barbuda
23 Mar, 2021: Emergency Use Authorization given by Vietnam
22 Mar, 2021: Emergency Use Authorization given by Mauritius
19 Mar, 2021: Emergency Use Authorization given by Cameroon
19 Mar, 2021: Emergency Use Authorization given by Philippines
19 Mar, 2021: Emergency Use Authorization given by Republic of Seychelles
12 Mar, 2021: Emergency Use Authorization given by Azerbaijan
11 Mar, 2021: Emergency Use Authorization given by Namibia
10 Mar, 2021: Emergency Use Authorization given by Jordan
10 Mar, 2021: Emergency Use Authorization given by Kenya
10 Mar, 2021: Emergency Use Authorization given by Morocco
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
7 Mar, 2021: Emergency Use Authorization given by Macedonia
7 Mar, 2021: Emergency Use Authorization given by North Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
4 Mar, 2021: Emergency Use Authorization given by Iraq
4 Mar, 2021: Emergency Use Authorization given by Laos
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
26 Feb, 2021: Emergency Use Authorization given by Republic of Moldova
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
23 Feb, 2021: Emergency Use Authorization given by Kyrgyzstan
23 Feb, 2021: Emergency Use Authorization given by Guyana
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
12 Feb, 2021: Emergency Use Authorization given by Saint Vincent and the Grenadines
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
9 Feb, 2021: Emergency Use Authorization given by Mongolia
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
14 Jan, 2021: Temporary Registration given by Kazakhstan
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
31 Dec, 2020: Emergency Use Authorization given by Serbia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: EUA given by Russia
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 9

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all COVID-19 and 90% efficacy in preventing severe COVID-19 with just a single dose.

Early Approval - 25 June 2020
Trial Start Date - 15 September 2020
Result Publication Date - 01 February 2021
22 Mar, 2022: Emergency Use Authorization given by Indonesia
22 Mar, 2022: Emergency Use Authorization given by Malaysia
19 Feb, 2022: Complete approval given by China
07 Sep, 2021: Emergency Use Authorization given by Indonesia
16 Jun, 2021: Complete approval given by Ecuador
15 Jun, 2021: Emergency Use Authorization given by Malaysia
12 Jun, 2021: Emergency Use Authorization given by Argentina
8 Apr, 2021: Emergency Use Authorization given by Chile
22 Mar, 2021: Emergency Use Authorization given by Hungary
12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Today

Sinopharm 60,000 2 2 - 8°C 86.0% 36

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 10 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 31 December 2020
22 Mar, 2022: Emergency Use Authorization given by Indonesia
07 Feb, 2022: Emergency Use Authorization given by South Africa
05 Feb, 2022: Emergency Use Authorization given by Thailand
28 Dec, 2021: Emergency Use Authorization given by UAE
12 Nov, 2021: Emergency Use Authorization given by Pakistan
2 Oct, 2021: Emergency Use Authorization given by Argentina
21 Aug, 2021: Emergency Use Authorization given by Mexico
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
24 Aug, 2021: Emergency Use Authorization given by Nigeria
19 Aug, 2021: Emergency Use Authorization given by Kenya
16 Jul, 2021: Emergency Use Authorization given by Malaysia
12 Jul, 2021: Emergency Use Authorization given by Tunisia
9 Jul, 2021: Emergency Use Authorization given by Trinidad and Tobago
18 Jun, 2021: Emergency Use Authorization given by Gambia
11 Jun, 2021: Emergency Use Authorization given by China
7 Jun, 2021: Emergency Use Authorization given by Philippines
4 June, 2021: Emergency Use Authorization given by Vietnam
2 Jun, 2021: Emergency Use Authorization given by Zambia
29 May, 2021: Emergency Use Authorization given by Bangladesh
28 May, 2021: Emergency Use Authorization given by Thailand
07 May, 2021: Emergency Use Authorization given by WHO
29 Apr, 2021: Emergency Use Authorization given by Indonesia
20 Mar, 2021: Emergency Use Authorization given by Sri Lanka
16 Mar, 2021: Emergency Use Authorization given by Maldives
11 Mar, 2021: Emergency Use Authorization given by Iran
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
1 Mar, 2021: Emergency Use Authorization given by Venezuela
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
18-Feb, 2021: Emergency Use Authorization given by Nepal
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

Bharat Biotech 25,800 2 2 - 8°C 81.0% 13

Adjuvanted inactivated vaccine produced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.

Early Approval - 03 January 2021
Trial Start Date - 16 November 2020
Result Publication Date - 01 March 2021
11 Feb, 2022: Emergency Use Authorization given by Malaysia
27 Jan, 2022: Emergency Use Authorization given by India
27 Dec, 2021: Emergency Use Authorization given by India
12 Nov, 2021: Emergency Use Authorization given by Bahrain
10 Nov, 2021: Emergency Use Authorization given by Hong Kong
10 Nov, 2021: Emergency Use Authorization given by Hong Kong
8 Nov, 2021: Emergency Use Authorization given by Trinidad and Tobago
3 Nov, 2021: Emergency Use Authorization given by WHO
2 Nov, 2021: Emergency Use Authorization given by Guyana
12 Oct, 2021: Emergency Use Authorization given by India
20 Apr, 2021: Emergency Use Authorization given by Philippines
6 Apr, 2021: Emergency Use Authorization given by Mexico
26 Mar, 2021: Complete Approval given by Mauritius
21 Mar, 2021: Emergency Use Authorization given by Nepal
04 Mar, 2021: Emergency Use Authorization given by Zimbabwe
19 Feb, 2021: Emergency Use Authorization given by Iran
3 Jan, 2021: Restricted Emergency Use Authorization given by India
Today

Gamaleya - Sputnik Light 110 1 2 - 8°C 79.4% 23

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, showed 79.4% efficacy from 28 days after the injection was administered as part of Russia’s mass vaccination program.

Early Approval - 06 May 2021
Trial Start Date - 15 January 2021
Result Publication Date - 06 May 2021
7 Feb, 2022: Restricted Emergency Use Authorization given by India
29 Dec, 2021: Complete Approval given by Tunisia
6 Dec, 2021: Emergency Use Authorization given by Argentina
30 Nov, 2021: Emergency Use Authorization given by UAE
23 Nov, 2021: Emergency Use Authorization given by Laos
23 Nov, 2021: Emergency Use Authorization given by San Marino
31 Oct, 2021: Emergency Use Authorization given by Cambodia
6 Oct, 2021: Emergency Use Authorization given by UAE
24 Sep, 2021: Emergency Use Authorization given by Egypt
16 Sep, 2021: Emergency Use Authorization given by Iran
06 Sep, 2021: Complete Approval given by Armenia
23 Aug, 2021: Emergency Use Authorization given by Philippines
15 Jul, 2021: Complete Approval given by Kazakhstan
25 Jun, 2021: Emergency Use Authorization given by Kyrgyzstan
11 Jun, 2021: Emergency Use Authorization given by Mongolia
7 Jun, 2021: Emergency Use Authorization given by Republic of the Congo
3 Jun, 2021: Emergency Use Authorization given by Belarus
2 Jun, 2021: Emergency Use Authorization given by Mauritius
31 May, 2021: Emergency Use Authorization given by Palestine
21 May, 2021: Emergency Use Authorization given by Nicaragua
15 May, 2021: Emergency Use Authorization given by Venezuela
12 May, 2021: Emergency Use Authorization given by Angola
11 May, 2021: Emergency Use Authorization given by Bahrain
6 May, 2021: Complete Approval given by Russia
Today

Cadila Healthcare Ltd - ZyCoV-D 28,000 3 2 - 8°C 66.6% 1

ZyCoV-D is the first plasmid DNA, needle-free vaccine against COVID-19, showing 66.6% efficacy after the third injection was administered in over 28,000 volunteers at more than 50 clinical sites spread across India.

Early Approval - 20 August 2021
Trial Start Date - 20 January 2021
Result Publication Date - 01 July 2021
20 Aug, 2021: Emergency Use Authorization given by India
Today

Biological E Ltd - CORBEVAX 3,000 2 2 - 8°C 90.0% 2

CORBEVAX is a recombinant protein sub-unit vaccine, developed from the receptor binding domain (RBD) of the spike protein on the virus’s surface combined with Dynavax’s CpG 1018 adjuvant with alum. It Showed >90% efficacy against Wuhan strain and >80% efficacy against Delta Strain.

Early Approval - 28 December 2021
Trial Start Date - 01 January 1970
Result Publication Date - 01 January 1970
29 Mar, 2022: Complete Approval given by Botswana
28 Dec, 2021: Restricted Emergency Use Authorization given by India
28 Dec, 2021: Restricted Emergency Use Authorization given by India
Today

Medicago Inc - COVIFENZ 753 2 2 - 8°C 71.0% 1

COVIFENZ is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs) using Coronavirus-Like Particle (CoVLP) technology and is co-administered with GSK’s pandemic adjuvant. The vaccination regimen calls for two doses given intramuscularly 21 days apart. The vaccine is stored at 2 °C to 8 °C.

Early Approval - 07 December 2021
Trial Start Date - 19 November 2020
Result Publication Date - 24 February 2022
24 Feb, 2022: Complete Approval given by Canada
Today

Valneva SE - VLA2001 4 2 2 - 8°C 95% 2

VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.

Early Approval - 18 October 2021
Trial Start Date - 26 April 2021
Result Publication Date - 01 March 2022
14 Apr, 2022: Complete Approval given by UK
1 Mar, 2022: Emergency Use Authorization given by Bahrain
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU